Psychemedics Statistics
Total Valuation
Psychemedics has a market cap or net worth of 12.85 million. The enterprise value is 12.60 million.
| Market Cap | 12.85M |
| Enterprise Value | 12.60M |
Important Dates
The next estimated earnings date is Wednesday, November 12, 2025.
| Earnings Date | Nov 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Psychemedics has 6.12 million shares outstanding. The number of shares has increased by 2.21% in one year.
| Current Share Class | 6.12M |
| Shares Outstanding | 6.12M |
| Shares Change (YoY) | +2.21% |
| Shares Change (QoQ) | +1.58% |
| Owned by Insiders (%) | 22.37% |
| Owned by Institutions (%) | 4.51% |
| Float | 2.98M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.65 |
| PB Ratio | 2.51 |
| P/TBV Ratio | 2.51 |
| P/FCF Ratio | 14.64 |
| P/OCF Ratio | 13.83 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -6.77 |
| EV / Sales | 0.64 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 14.35 |
Financial Position
The company has a current ratio of 1.82, with a Debt / Equity ratio of 0.23.
| Current Ratio | 1.82 |
| Quick Ratio | 1.45 |
| Debt / Equity | 0.23 |
| Debt / EBITDA | n/a |
| Debt / FCF | 1.33 |
| Interest Coverage | -72.81 |
Financial Efficiency
Return on equity (ROE) is -31.54% and return on invested capital (ROIC) is -15.50%.
| Return on Equity (ROE) | -31.54% |
| Return on Assets (ROA) | -11.46% |
| Return on Invested Capital (ROIC) | -15.50% |
| Return on Capital Employed (ROCE) | -33.76% |
| Revenue Per Employee | 194,901 |
| Profits Per Employee | -18,426 |
| Employee Count | 101 |
| Asset Turnover | 1.91 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -55,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | 0.55 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 2.14 |
| 200-Day Moving Average | 2.21 |
| Relative Strength Index (RSI) | 39.51 |
| Average Volume (20 Days) | 873 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.03 |
Income Statement
In the last 12 months, Psychemedics had revenue of 19.69 million and -1.86 million in losses. Loss per share was -0.32.
| Revenue | 19.69M |
| Gross Profit | 7.10M |
| Operating Income | -1.89M |
| Pretax Income | -1.92M |
| Net Income | -1.86M |
| EBITDA | -876,000 |
| EBIT | -1.89M |
| Loss Per Share | -0.32 |
Balance Sheet
The company has 1.42 million in cash and 1.17 million in debt, giving a net cash position of 251,000 or 0.04 per share.
| Cash & Cash Equivalents | 1.42M |
| Total Debt | 1.17M |
| Net Cash | 251,000 |
| Net Cash Per Share | 0.04 |
| Equity (Book Value) | 5.13M |
| Book Value Per Share | 0.84 |
| Working Capital | 2.23M |
Cash Flow
In the last 12 months, operating cash flow was 929,000 and capital expenditures -51,000, giving a free cash flow of 878,000.
| Operating Cash Flow | 929,000 |
| Capital Expenditures | -51,000 |
| Free Cash Flow | 878,000 |
| FCF Per Share | 0.14 |
Margins
Gross margin is 36.07%, with operating and profit margins of -9.62% and -9.45%.
| Gross Margin | 36.07% |
| Operating Margin | -9.62% |
| Pretax Margin | -9.73% |
| Profit Margin | -9.45% |
| EBITDA Margin | -4.45% |
| EBIT Margin | -9.62% |
| FCF Margin | 4.46% |
Dividends & Yields
Psychemedics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.21% |
| Shareholder Yield | -2.21% |
| Earnings Yield | -14.48% |
| FCF Yield | 6.83% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | Dec 4, 2024 |
| Split Type | n/a |
| Split Ratio | 1 |
Scores
Psychemedics has an Altman Z-Score of 1.62 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.62 |
| Piotroski F-Score | 4 |